NCT07101328

A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 )

BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 215 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell lymphoma.

Conditions

• Lymphoma, Non-Hodgkin
• B-cell Lymphoma
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Follicular

Interventions

Type	Name	Description
DRUG	LY4152199 - IV	Administered by IV infusion

Timeline

• Start date: 2026-06-01
• Primary completion: 2027-04-01
• Completion: 2029-03-01
• First posted: 2025-08-03
• Last updated: 2026-03-20

Locations

50 sites across 12 countries: United States, Australia, Canada, Denmark, France, Germany, Italy, Japan, Poland, South Korea, Spain, United Kingdom

Regulatory

• FDA-regulated drug study